Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + belantamab mafodotin + dexamethasone in relapsed or refractory multiple myeloma
2024-514989-40-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of isatuximab, belantamab mafodotin and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoints: Recommended dose determination and Very good partial response rate or better. Planned start May 2021; status: authorised.
02
Drugs
isatuximabbelantamab mafodotindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514989-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514989-40-00.